RECOVERY Collaborative Group, et al. - Researchers sought to summarize the outcomes of a randomized trial investigating the effects of lopinavir–ritonavir on outcomes in patients admitted to hospital with COVID-19. In this randomized, controlled, open-label, platform trial, random allocation of 1,616 patients to receive lopinavir–ritonavir and 3,424 patients to receive usual care was performed. Outcomes revealed no correlation of providing lopinavir–ritonavir with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death in patients admitted to hospital with COVID-19. Findings thereby yield no support for using lopinavir–ritonavir for treatment of patients admitted to hospital with COVID-19.